Finance

Lists
Outlook: 41.9% bullish·4.7% bearish
Go to analysis
PFE:NYSE
Pfizer Inc
$28.67
+0.92%
(+0.26) 1D
$28.60
-0.24% (-0.070)
Pre-market
Closed: Sep 25, 4:01:46 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PFE...
Open
$28.45
High
$28.69
Low
$28.17
Mkt. cap
163.41B
Avg. vol.
33.83M
Volume
91.61K
Dividend
6.00%
Quarterly dividend
$0.43
Ex-dividend date
Jul 24, 2026
P/E ratio
37.96
52-wk high
$29.21
52-wk low
$23.61
EPS
$0.76
Beta
0.34
Shares outstanding
5.70B
No. of employees
75K
Open
$28.45
High
$28.69
Low
$28.17
Mkt. cap
163.41B
Avg. vol.
33.83M
Volume
91.61K
Dividend
6.00%
Quarterly dividend
$0.43
Ex-dividend date
Jul 24, 2026
P/E ratio
37.96
52-wk high
$29.21
52-wk low
$23.61
EPS
$0.76
Beta
0.34
Shares outstanding
5.70B
No. of employees
75K
News stories
From web sources and news partners
Profile
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America. Pfizer develops and produces medication and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company's largest products by sales are Eliquis, Prevnar, Paxlovid, Vyndaqel, Comirnaty, and Ibrance. In 2025, 59% of the company's revenues came from the United States, 5% came from China, and 36% came from other countries. The company is ranked fifth on the list of largest biomedical companies by revenue. It is ranked the 69th on the Fortune 500 and 73rd on the Forbes Global 2000. Wikipedia
About Pfizer Inc
CEOAlbert Bourla
Employees75K
Founded1849
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitepfizer.com
Analyst ratings
Based on 20 analysts giving stock ratings to PFE in the past 3 months
Buy
Buy
7
Hold
12
Sell
1
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for PFE in the last 3 months.
Highest
Current $28.67
$35.75 (+24.69%)
Average
$28.67 (0.00%)
Lowest
$25.00 (-12.80%)
Analyst
Recommendation
Action
Price target
Projected
Date
Chris Schott
J.P. Morgan
Hold
Maintained
$28.00
-2.3%
09/25/2026
Courtney Breen
Bernstein
Hold
Maintained
$29.00
+1.2%
09/22/2026
Mohit Bansal
Wells Fargo
Hold
Maintained
$28.00
-2.3%
09/21/2026
Trung Huynh
RBC Capital
Hold
Maintained
$25.00
-12.8%
09/21/2026
Rajesh Kumar
HSBC
Hold
Maintained
$30.00
+4.6%
09/10/2026
Louise Chen
Scotiabank
Buy
Maintained
$30.00
+4.6%
08/24/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$30.00
+4.6%
08/17/2026
Emily Field
Barclays
Sell
Maintained
$25.00
-12.8%
08/13/2026
Steve Scala
TD Cowen
Hold
Maintained
-
-
08/11/2026
Jill Wu
CMB International Securities
Buy
Maintained
$35.75
+24.7%
08/07/2026
Vamil Divan
Guggenheim
Buy
Maintained
$31.00
+8.1%
08/06/2026
David Toung
Argus Research
Buy
Maintained
-
-
08/05/2026
Elmar Kraus
DZ BANK AG
Buy
Maintained
-
-
08/06/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$28.00
-2.3%
08/04/2026
Carter Gould
Cantor Fitzgerald
Hold
Maintained
$27.00
-5.8%
08/04/2026
Kerry Holford
Berenberg Bank
Hold
Maintained
$25.00
-12.8%
08/05/2026
Geoff Meacham
Citi
Hold
Maintained
-
-
08/05/2026
Asad Haider
Goldman Sachs
Hold
Maintained
$26.00
-9.3%
08/04/2026
Jason Gerberry
Bank of America Securities
Hold
Reiterated
$27.00
-5.8%
08/04/2026
Akash Tewari
Jefferies
Buy
Maintained
$34.00
+18.6%
08/05/2026
Michael Yee
UBS
Hold
Maintained
$27.00
-5.8%
06/23/2026
Alexandria Hammond
Wolfe Research
Sell
Reiterated
$26.00
-9.3%
05/13/2026
Hans Engel
Erste Group
Hold
Maintained
-
-
05/05/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
04/27/2026
Narumi Nakagiri
Daiwa
Hold
Downgraded
$27.00
-5.8%
02/12/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.77 / $0.68
+12.87%beat
Revenue / Est. (USD)
15.03B / 14.39B
+4.49%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
16.65B
17.56B
14.45B
15.03B
Cost of goods sold
3.98B
5.06B
3.41B
3.66B
Cost of revenue
3.98B
5.06B
3.41B
3.66B
Research and development expenses
2.49B
3.32B
2.45B
2.75B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.08B
3.74B
2.84B
3.26B
Operating expense
6.80B
8.29B
6.48B
7.19B
Total operating expenses
10.78B
13.35B
9.88B
10.84B
Operating income
5.88B
4.20B
4.57B
4.19B
Other non operating income
181.00M
1.35B
36.00M
515.00M
EBT including unusual items
3.33B
-1.64B
3.17B
-653.00M
EBT excluding unusual items
5.54B
5.09B
4.13B
4.25B
Income tax expense
-216.00M
-2.00M
461.00M
-407.00M
Effective tax rate
-6.48%
0.12%
14.55%
62.33%
Other operating expenses
-
-
-
-
Net income
3.54B
-1.65B
2.69B
-248.00M
Net profit margin
21.26%
-9.39%
18.59%
-1.65%
Earnings per share
0.87
0.66
0.75
0.77
Interest and investment income
138.00M
247.00M
197.00M
211.00M
Interest expense
-652.00M
-711.00M
-668.00M
-667.00M
Net interest expenses
-514.00M
-464.00M
-471.00M
-456.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
7.53B
5.86B
6.18B
5.80B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps